CCA
AEGR

Catalyst Capital Advisors’s Aegerion Pharmaceuticals AEGR Stock Holding History

Catalyst Capital Advisors’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-132,500
Closed -$4.42M – 591
2014
Q3 		$4.42M Buy
132,500
+46,000
+53% +$1.43M 0.57% 55
2014
Q2 		$2.78M Buy
+86,500
New +$3.22M 0.45% 80

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Catalyst Capital Advisors's AEGR Position: Q4 2014 in Review

Catalyst Capital Advisors sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2014, closing a stake of 132,500 shares — an estimated $4.42M sold.

Catalyst Capital Advisors first reported a position in AEGR in Q2 2014 and held it in 2 quarters. The position peaked at $4.42M in Q3 2014. 95 funds tracked by Wall St. Rank hold AEGR as of Q4 2014.

  • Catalyst Capital Advisors reported no remaining Aegerion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Catalyst Capital Advisors sold 132,500 Aegerion Pharmaceuticals shares in Q4 2014, an estimated $4.42M.
  • Catalyst Capital Advisors first reported a position in Aegerion Pharmaceuticals in Q2 2014 and held it in 2 quarters.
  • Catalyst Capital Advisors's Aegerion Pharmaceuticals position peaked at $4.42M in Q3 2014.
  • 95 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2014.

Based on Catalyst Capital Advisors's 13F filing for Q4 2014, filed 10 Feb 2015.